

External Quality Assessment Scheme

Toxoplasma, antibodies Round 1, 2023

Specimens

Please find enclosed 3 human plasma samples S001, S002 and S003, each 0.7mL.

Caution

Quality control specimens derived from human blood must be handled with the same care as patient samples, i.e. as potential transmitters of serious diseases. The specimens are found to be HBsAg, HCVAb and HIVAgAb negative when tested with licensed reagents, but no known test method can offer complete assurance that the specimens will not transmit these or other infectious diseases.

Background information

S001: A 48-year-old female. 3 weeks history of lymphadenopathy.

S002: A 10-year-old child with prolonged fever and lymphadenopathy.

S003: A 40-year-old male. Newly diagnosed as HIV positive.

Examinations

ToxoAb
ToxoAbA
ToxoAbG
ToxoAbM
ToxoAvi
Clinical interpretation

Storage and use

After arrival, the samples should be stored at +2...8 °C, analysed as soon as possible, preferably within a week. Samples are ready for use. Analyse as patient samples.

Result reporting

Please enter the results and methods via LabScala (www.labscala.com). If you cannot find your instrument or reagent from the registry, please contact the EQA Coordinator. Report only the results of examinations that are in use in your laboratory. All the reported test results are scored.

S001:



S002:



S003:



2023-01-31

INSTRUCTIONS

Product no. 5420
LQ769723011-013/FI

Subcontracting: Sample preparation, Sample pretesting

If the kit is incomplete or contains damaged specimens, please report immediately to info@labquality.fi

The results should be reported no later than **February 24, 2023.**

Expected results of the round are published in LabScala in the view reports section by March 1, 2023.

Inquiries

EQA Coordinator
Pia Eloranta
pia.eloranta@labquality.fi

EQA Coordinator
Outi Rauta
outi.rauta@labquality.fi

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200
Fax + 358 9 8566 8280


info@labquality.fi
www.labquality.com



Client report

	No of participants	No of responded participants	Response percentage
Toxoplasma, antibodies, February, 1-2023	116	113	97.4 %

Summary




Summary	Own score	Max score	Own success rate	Difference	AVR success rate
Sample S001	4	4	100 %	3.5 %	96.5 %
Sample S002	4	4	100 %	3.8 %	96.2 %
Sample S003	4	4	100 %	0.7 %	99.3 %
Average:			100 %	2.7 %	97.3 %

History	Test nr.	Own success rate	Difference	AVR success rate
Round 2022-4	1-1	100 %	12.8 %	87.2 %
Round 2022-1	1-1	100 %	6.6 %	93.4 %
Round 2021-4	1-1	100 %	4.6 %	95.4 %
Round 2021-1	1-1	100 %	2.1 %	97.9 %
Round 2020-4	1-1	100 %	5.3 %	94.7 %
Round 2020-1	1-1	100 %	5.2 %	94.8 %
Round 2019-4	1-1	100 %	6.4 %	93.6 %
Round 2019-1	1-1	100 %	5.5 %	94.5 %


Sample S001

Sample S001 success rate



Sample S001 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	-	-	-	-	91 %	126
	ToxoAb	-	-	-	-	100 %	2
	ToxoAbA	-	-	-	-	100 %	8
	ToxoAbG	2	2	100 %	0 %	100 %	125
	ToxoAbM	2	2	100 %	0 %	100 %	123
	Toxo IgG Avidity	-	-	-	-	95.2 %	42
Total:		4	4	100 %	3.5 %	96.5 %	426

Sample S001 Clinical interpretation



Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	Own score	Max score	Own success rate	Difference	AVR success rate
	Primary infection		10		-	-			100 %
		New sample requested		2	-	-			
		Would be referred to another laboratory for further examination		2	-	-			
	Acute/recent infection		61		-	-			100 %
		Would be referred to another laboratory for further examination		13	-	-			
		New sample requested		15	-	-			
	Previous infection, no indication of primary infection		1		-	-			0 %
		New sample requested		1	-	-			
	Reactivation/reinfection		6		-	-			0 %
		Would be referred to another laboratory for further examination		2	-	-			


		New sample requested		1	-	-			
	<input checked="" type="radio"/> Laboratory does not give clinical interpretation		48		-				-
		Would be referred to another laboratory for further examination		8	-	-			
		New sample requested		3	-	-			
	Total:		126		-	-	-	-	91 %

Sample S001 ToxoAb




Positive

Sample S001 ToxoAbA



Positive

Sample S001 ToxoAbG




Positive

Sample S001 ToxoAbM



Positive

Sample S001 Toxo IgG Avidity



Not measurable Strong avidity Weak avidity

ToxoAb	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Positive		2		-				100 %
		bioMérieux Vidas Toxo Competition		1					

		Euroimmun Anti-Toxoplasma gondii Screen ELISA (IgAGM)		1					
	Total:		2		-	-	-	-	100 %

ToxoAbA	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Positive		8		-				100 %
		BioRad Platelia Toxo IgA EIA		4					
		Chorus Toxo IgA		2					
		Euroimmun Anti-Toxoplasma gondii IgA ELISA		2					
	Total:		8		-	-	-	-	100 %

OWN DEVICE: CI4100

ToxoAbG	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Positive		125		2	2	100 %	0 %	100 %
		Abbott Alinity Toxo IgG		21					
		<input checked="" type="radio"/> Abbott Architect Toxo IgG		16					
		Bayer Advia Centaur Toxoplasma IgG		2					
		Beckman Coulter Access Toxo IgG EIA		1					
		bioMérieux Vidas Toxo IgG		12					
		BioRad Platelia Toxo IgG EIA		6					
		Chorus Toxo IgG		1					
		Diasorin Liaison Toxo IgG		29					
		Euroimmun Anti-Toxoplasma gondii IgG ELISA		2					
		Euroimmun Anti-Toxoplasma gondii IgG IIFT		2					
		Novatec NovaLisa Toxoplasma gondii IgG ELISA		1					
		Roche cobas/Modular/Elecsys Toxo IgG		26					
		Siemens Atellica Toxo IgG		4					
		Siemens Immulite Toxoplasma IgG		2					
	Total:		125		2	2	100 %	0 %	100 %

OWN DEVICE: CI4100


ToxoAbM	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Positive		123		2	2	100 %	0 %	100 %
		Abbott Alinity Toxo IgM		19					
		<input checked="" type="radio"/> Abbott Architect Toxo IgM		15					
		Bayer Advia Centaur Toxoplasma IgM		2					
		Beckman Coulter Access Toxo IgM EIA		2					
		bioMérieux Vidas Toxo IgM		12					
		BioRad Platelia Toxo IgM EIA		6					
		Chorus Toxo IgM		1					
		Diasorin Liaison Toxo IgM		28					
		Euroimmun Anti-Toxoplasma gondii IgM ELISA		1					
		Euroimmun Anti-Toxoplasma gondii IgM IIFT		2					
		Novatec NovaLisa Toxoplasma gondii IgM ELISA		2					
		Roche cobas/Modular/Elecsys Toxo IgM		27					
		Siemens Atellica Toxo IgM		4					
		Siemens Immulite Toxoplasma IgM		2					
	Total:		123		2	2	100 %	0 %	100 %

Toxo IgG Avidity	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Not measurable		1		-				0 %
		Chorus Toxo IgG Avidity		1					
	Strong avidity		1		-				0 %

		Novatec Novalisa Toxoplasma gondii IgG Avidity ELISA		1					
	Weak avidity		40		-				100 %
		Abbott Alinity Toxo IgG avidity		6					
		Abbott Architect Toxo IgG Avidity		3					
		bioMérieux Vidas Toxo IgG Avidity		11					
		BioRad Platelia Toxo IgG Avidity EIA		2					
		Chorus Toxo IgG Avidity		1					
		Diasorin Liaison Toxo IgG Avidity		8					
		Euroimmun Anti-Toxoplasma gondii IgG Avidity ELISA		3					
		Roche cobas/Modular/Elecsys Toxo IgG Avidity		5					
		TestLine Toxoplasma IgG Avidity EIA		1					
	Total:		42		-	-	-	-	95.2 %


Sample S002

Sample S002 success rate



Sample S002 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	-	-	-	-	90.8 %	126
	ToxoAb	-	-	-	-	100 %	2
	ToxoAbA	-	-	-	-	87.5 %	8
	ToxoAbG	2	2	100 %	0 %	100 %	125
	ToxoAbM	2	2	100 %	0 %	100 %	123
	Toxo IgG Avidity	-	-	-	-	95.2 %	42
Total:		4	4	100 %	3.8 %	96.2 %	426

Sample S002 Clinical interpretation



Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	Own score	Max score	Own success rate	Difference	AVR success rate
	Primary infection		9		-	-			100 %
		New sample requested		1	-	-			
		Would be referred to another laboratory for further examination		1	-	-			
	Acute/recent infection		60		-	-			100 %
		New sample requested		15	-	-			
		Would be referred to another laboratory for further examination		15	-	-			
	Previous infection, no indication of acute/recent infection		1		-	-			0 %
		New sample requested		1	-	-			
		Would be referred to another laboratory for further examination		1	-	-			
	Reactivation/reinfection		6		-	-			0 %


		New sample requested		2	-	-			
	<input checked="" type="radio"/> Laboratory does not give clinical interpretation		50		-				-
		New sample requested		3	-	-			
		Would be referred to another laboratory for further examination		8	-	-			
	Total:		126		-	-	-	-	90.8 %

Sample S002 ToxoAb




Positive

Sample S002 ToxoAbA



Negative Positive

Sample S002 ToxoAbG




Positive

Sample S002 ToxoAbM



Positive

Sample S002 Toxo IgG Avidity



Not measurable Strong avidity Weak avidity

ToxoAb	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Positive		2		-				100 %
		bioMérieux Vidas Toxo Competition		1					

		Euroimmun Anti-Toxoplasma gondii Screen ELISA (IgAGM)		1					
	Total:		2		-	-	-	-	100 %

ToxoAbA	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		1		-				0 %
		Chorus Toxo IgA		1					
	Positive		7		-				100 %
		BioRad Platelia Toxo IgA EIA		4					
		Chorus Toxo IgA		1					
		Euroimmun Anti-Toxoplasma gondii IgA ELISA		2					
	Total:		8		-	-	-	-	87.5 %

OWN DEVICE: CI4100

ToxoAbG	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Positive		125		2	2	100 %	0 %	100 %
		Abbott Alinity Toxo IgG		21					
		<input checked="" type="radio"/> Abbott Architect Toxo IgG		16					
		Bayer Advia Centaur Toxoplasma IgG		2					
		Beckman Coulter Access Toxo IgG EIA		1					
		bioMérieux Vidas Toxo IgG		12					
		BioRad Platelia Toxo IgG EIA		6					
		Chorus Toxo IgG		1					
		Diasorin Liaison Toxo IgG		29					
		Euroimmun Anti-Toxoplasma gondii IgG ELISA		2					
		Euroimmun Anti-Toxoplasma gondii IgG IIFT		2					
		Novatec NovaLisa Toxoplasma gondii IgG ELISA		1					
		Roche cobas/Modular/Elecsys Toxo IgG		26					
		Siemens Atellica Toxo IgG		4					
		Siemens Immulite Toxoplasma IgG		2					
	Total:		125		2	2	100 %	0 %	100 %

OWN DEVICE: CI4100


ToxoAbM	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Positive		123		2	2	100 %	0 %	100 %
		Abbott Alinity Toxo IgM		19					
		<input checked="" type="radio"/> Abbott Architect Toxo IgM		15					
		Bayer Advia Centaur Toxoplasma IgM		2					
		Beckman Coulter Access Toxo IgM EIA		2					
		bioMérieux Vidas Toxo IgM		12					
		BioRad Platelia Toxo IgM EIA		6					
		Chorus Toxo IgM		1					
		Diasorin Liaison Toxo IgM		28					
		Euroimmun Anti-Toxoplasma gondii IgM ELISA		1					
		Euroimmun Anti-Toxoplasma gondii IgM IIFT		2					
		Novatec NovaLisa Toxoplasma gondii IgM ELISA		2					
		Roche cobas/Modular/Elecsys Toxo IgM		27					
		Siemens Atellica Toxo IgM		4					
		Siemens Immulite Toxoplasma IgM		2					
	Total:		123		2	2	100 %	0 %	100 %

Toxo IgG Avidity	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Not measurable		1		-				0 %

		Chorus Toxo IgG Avidity		1					
	Strong avidity		1		-				0 %
		Novatec NovaLisa Toxoplasma gondii IgG Avidity ELISA		1					
	Weak avidity		40		-				100 %
		Abbott Alinity Toxo IgG avidity		6					
		Abbott Architect Toxo IgG Avidity		3					
		bioMérieux Vidas Toxo IgG Avidity		11					
		BioRad Platelia Toxo IgG Avidity EIA		2					
		Chorus Toxo IgG Avidity		1					
		Diasorin Liaison Toxo IgG Avidity		8					
		Euroimmun Anti-Toxoplasma gondii IgG Avidity ELISA		3					
		Roche cobas/Modular/Elecsys Toxo IgG Avidity		5					
		TestLine Toxoplasma IgG Avidity EIA		1					
	Total:		42		-	-	-	-	95.2 %


Sample S003

Sample S003 success rate



Sample S003 results	Responded	Own score	Max score	Own success rate	Difference	AVR success rate	Count
	Clinical interpretation	-	-	-	-	100 %	126
	ToxoAb	-	-	-	-	100 %	2
	ToxoAbA	-	-	-	-	-	8
	ToxoAbG	2	2	100 %	0 %	100 %	125
	ToxoAbM	2	2	100 %	0 %	100 %	123
	Toxo IgG Avidity	-	-	-	-	91.2 %	34
	Total:	4	4	100 %	0.7 %	99.3 %	418


Sample S003 Clinical interpretation



- Previous infection, no indication of primary infection
- Previous infection, no indication of acute/recent infection
- Laboratory does not give clinical interpretation


Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	Own score	Max score	Own success rate	Difference	AVR success rate
	Previous infection, no indication of primary infection		18		-				100 %
		New sample requested		2	-	-			
		Would be referred to another laboratory for further examination		2	-	-			
	Previous infection, no indication of acute/recent infection		58		-				100 %
		New sample requested		7	-	-			
		Would be referred to another laboratory for further examination		6	-	-			
	⊙ Laboratory does not give clinical interpretation		50		-				-
		New sample requested		2	-	-			
		Would be referred to another laboratory for further examination		4	-	-			
	Total:		126		-	-	-	-	100 %

Sample S003 ToxoAb




Positive

Sample S003 ToxoAbA



Negative Borderline Positive

Sample S003 ToxoAbG



Positive

Sample S003 ToxoAbM



Negative

Sample S003 Toxo IgG Avidity



Not measurable Strong avidity Weak avidity

ToxoAb	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Positive		2		-				100 %
		bioMérieux Vidas Toxo Competition		1					
		Euroimmun Anti-Toxoplasma gondii Screen ELISA (IgAGM)		1					
	Total:		2		-	-	-	-	100 %
ToxoAbA	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Negative		3		-				-

		BioRad Platelia Toxo IgA EIA		2					
		Chorus Toxo IgA		1					
	Borderline		1		-				-
		BioRad Platelia Toxo IgA EIA		1					
	Positive		4		-				-
		BioRad Platelia Toxo IgA EIA		1					
		Chorus Toxo IgA		1					
		Euroimmun Anti-Toxoplasma gondii IgA ELISA		2					
	Total:		8		-	-	-	-	

OWN DEVICE: CI4100

ToxoAbG	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Positive		125		2	2	100 %	0 %	100 %
		Abbott Alinity Toxo IgG		21					
		<input checked="" type="radio"/> Abbott Architect Toxo IgG		16					
		Bayer Advia Centaur Toxoplasma IgG		2					
		Beckman Coulter Access Toxo IgG EIA		1					
		bioMérieux Vidas Toxo IgG		12					
		BioRad Platelia Toxo IgG EIA		6					
		Chorus Toxo IgG		1					
		Diasorin Liaison Toxo IgG		29					
		Euroimmun Anti-Toxoplasma gondii IgG ELISA		2					
		Euroimmun Anti-Toxoplasma gondii IgG IIFT		2					
		Novatec NovaLisa Toxoplasma gondii IgG ELISA		1					
		Roche cobas/Modular/Elecsys Toxo IgG		26					
		Siemens Atellica Toxo IgG		4					
		Siemens Immulite Toxoplasma IgG		2					
	Total:		125		2	2	100 %	0 %	100 %

OWN DEVICE: CI4100

ToxoAbM	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	<input checked="" type="radio"/> Negative		123		2	2	100 %	0 %	100 %
		Abbott Alinity Toxo IgM		19					
		<input checked="" type="radio"/> Abbott Architect Toxo IgM		15					
		Bayer Advia Centaur Toxoplasma IgM		2					
		Beckman Coulter Access Toxo IgM EIA		2					
		bioMérieux Vidas Toxo IgM		12					
		BioRad Platelia Toxo IgM EIA		6					
		Chorus Toxo IgM		1					
		Diasorin Liaison Toxo IgM		28					
		Euroimmun Anti-Toxoplasma gondii IgM ELISA		1					
		Euroimmun Anti-Toxoplasma gondii IgM IIFT		2					
		Novatec NovaLisa Toxoplasma gondii IgM ELISA		2					
		Roche cobas/Modular/Elecsys Toxo IgM		27					
		Siemens Atellica Toxo IgM		4					
		Siemens Immulite Toxoplasma IgM		2					
	Total:		123		2	2	100 %	0 %	100 %

Toxo IgG Avidity	Result	Methodics	Result count	Methodics count	Own score	Max score	Own success rate	Difference	AVR success rate
	Not measurable		1		-				0 %
		Chorus Toxo IgG Avidity		1					
	Strong avidity		31		-				100 %
		Abbott Alinity Toxo IgG avidity		2					
		Abbott Architect Toxo IgG Avidity		3					

		bioMérieux Vidas Toxo IgG Avidity		6				
		BioRad Platelia Toxo IgG Avidity EIA		2				
		Chorus Toxo IgG Avidity		1				
		Diasorin Liaison Toxo IgG Avidity		7				
		Euroimmun Anti-Toxoplasma gondii IgG Avidity ELISA		3				
		Novatec NovaLisa Toxoplasma gondii IgG Avidity ELISA		1				
		Roche cobas/Modular/Elecsys Toxo IgG Avidity		5				
		TestLine Toxoplasma IgG Avidity EIA		1				
	Weak avidity		2		-			0 %
		Abbott Alinity Toxo IgG avidity		2				
	Total:		34		-	-	-	91.2 %

Report Info**PARTICIPANTS**

Altogether 116 laboratories from 21 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points


The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

GLOBAL REPORT

	No of participants	No of responded participants	Response percentage
Toxoplasma, antibodies, February, 1-2023	116	113	97.4 %


Summary



Summary	AVR success rate
Sample S001	96.5 %
Sample S002	96.2 %
Sample S003	99.3 %
Average:	97.3 %


Sample S001

Sample S001 success rate



Sample S001 results	Responded	AVR success rate	Count
	Clinical interpretation	91 %	126
	ToxoAb	100 %	2
	ToxoAbA	100 %	8
	ToxoAbG	100 %	125
	ToxoAbM	100 %	123
	Toxo IgG Avidity	95.2 %	42
	Total:	96.5 %	426

Sample S001 Clinical interpretation



Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	AVR success rate	Clinical interpretation Score	Further handling Score
	Primary infection		10		100 %	4	
		New sample requested		2	-		-
		Would be referred to another laboratory for further examination		2	-		-
	Acute/recent infection		61		100 %	4	
		Would be referred to another laboratory for further examination		13	-		-
		New sample requested		15	-		-
	Previous infection, no indication of primary infection		1		0 %	0	
		New sample requested		1	-		-
	Reactivation/reinfection		6		0 %	0	
		Would be referred to another laboratory for further examination		2	-		-

		New sample requested		1	-		-
	Laboratory does not give clinical interpretation		48		-	-	
		Would be referred to another laboratory for further examination		8	-		-
		New sample requested		3	-		-
	Total:		126		91 %		

Sample S001 ToxoAb




Positive

Sample S001 ToxoAbA



Positive

Sample S001 ToxoAbG




Positive

Sample S001 ToxoAbM



Positive

Sample S001 Toxo IgG Avidity



Not measurable Strong avidity Weak avidity

ToxoAb	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Positive		2		100 %	2
		bioMérieux Vidas Toxo Competition		1		

		Euroimmun Anti-Toxoplasma gondii Screen ELISA (IgAGM)		1		
	Total:		2		100 %	

ToxoAbA	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Positive		8		100 %	2
		BioRad Platelia Toxo IgA EIA		4		
		Chorus Toxo IgA		2		
		Euroimmun Anti-Toxoplasma gondii IgA ELISA		2		
	Total:		8		100 %	

ToxoAbG	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Positive		125		100 %	2
		Abbott Alinity Toxo IgG		21		
		Abbott Architect Toxo IgG		16		
		Bayer Advia Centaur Toxoplasma IgG		2		
		Beckman Coulter Access Toxo IgG EIA		1		
		bioMérieux Vidas Toxo IgG		12		
		BioRad Platelia Toxo IgG EIA		6		
		Chorus Toxo IgG		1		
		Diasorin Liaison Toxo IgG		29		
		Euroimmun Anti-Toxoplasma gondii IgG ELISA		2		
		Euroimmun Anti-Toxoplasma gondii IgG IIFT		2		
		Novatec NovaLisa Toxoplasma gondii IgG ELISA		1		
		Roche cobas/Modular/Elecsys Toxo IgG		26		
		Siemens Atellica Toxo IgG		4		
		Siemens Immulite Toxoplasma IgG		2		
	Total:		125		100 %	


ToxoAbM	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Positive		123		100 %	2
		Abbott Alinity Toxo IgM		19		
		Abbott Architect Toxo IgM		15		
		Bayer Advia Centaur Toxoplasma IgM		2		
		Beckman Coulter Access Toxo IgM EIA		2		
		bioMérieux Vidas Toxo IgM		12		
		BioRad Platelia Toxo IgM EIA		6		
		Chorus Toxo IgM		1		
		Diasorin Liaison Toxo IgM		28		
		Euroimmun Anti-Toxoplasma gondii IgM ELISA		1		
		Euroimmun Anti-Toxoplasma gondii IgM IIFT		2		
		Novatec NovaLisa Toxoplasma gondii IgM ELISA		2		
		Roche cobas/Modular/Elecsys Toxo IgM		27		
		Siemens Atellica Toxo IgM		4		
		Siemens Immulite Toxoplasma IgM		2		
	Total:		123		100 %	

Toxo IgG Avidity	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Not measurable		1		0 %	0
		Chorus Toxo IgG Avidity		1		
	Strong avidity		1		0 %	0
		Novatec NovaLisa Toxoplasma gondii IgG Avidity ELISA		1		
	Weak avidity		40		100 %	2
		Abbott Alinity Toxo IgG avidity		6		
		Abbott Architect Toxo IgG Avidity		3		
		bioMérieux Vidas Toxo IgG Avidity		11		
		BioRad Platelia Toxo IgG Avidity EIA		2		
		Chorus Toxo IgG Avidity		1		
		Diasorin Liaison Toxo IgG Avidity		8		
		Euroimmun Anti-Toxoplasma gondii IgG Avidity ELISA		3		
		Roche cobas/Modular/Elecsys Toxo IgG Avidity		5		
		TestLine Toxoplasma IgG Avidity EIA		1		

	Total:		42		95.2 %	
--	--------	--	----	--	--------	--


Sample S002

Sample S002 success rate



Sample S002 results	Responded	AVR success rate	Count
	Clinical interpretation	90.8 %	126
	ToxoAb	100 %	2
	ToxoAbA	87.5 %	8
	ToxoAbG	100 %	125
	ToxoAbM	100 %	123
	Toxo IgG Avidity	95.2 %	42
	Total:	96.2 %	426

Sample S002 Clinical interpretation



■ Primary infection ■ Acute/recent infection
■ Previous infection, no indication of acute/recent infection
■ Reactivation/reinfection ■ Laboratory does not give clinical interpretation

Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	AVR success rate	Clinical interpretation Score	Further handling Score
	Primary infection		9		100 %	4	
		New sample requested		1	-		-
		Would be referred to another laboratory for further examination		1	-		-
	Acute/recent infection		60		100 %	4	
		New sample requested		15	-		-
		Would be referred to another laboratory for further examination		15	-		-
	Previous infection, no indication of acute/recent infection		1		0 %	0	
		New sample requested		1	-		-
		Would be referred to another laboratory for further examination		1	-		-
	Reactivation/reinfection		6		0 %	0	


		New sample requested		2	-		-
	Laboratory does not give clinical interpretation		50		-	-	
		New sample requested		3	-		-
		Would be referred to another laboratory for further examination		8	-		-
	Total:		126		90.8 %		

Sample S002 ToxoAb



Positive

Sample S002 ToxoAbA



Negative Positive

Sample S002 ToxoAbG




Positive

Sample S002 ToxoAbM



Positive

Sample S002 Toxo IgG Avidity



Not measurable Strong avidity Weak avidity

ToxoAb	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Positive		2		100 %	2
		bioMérieux Vidas Toxo Competition		1		

		Euroimmun Anti-Toxoplasma gondii Screen ELISA (IgAGM)		1		
	Total:		2		100 %	

ToxoAbA	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Negative		1		0 %	0
		Chorus Toxo IgA		1		
	Positive		7		100 %	2
		BioRad Platelia Toxo IgA EIA		4		
		Chorus Toxo IgA		1		
		Euroimmun Anti-Toxoplasma gondii IgA ELISA		2		
	Total:		8		87.5 %	

ToxoAbG	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Positive		125		100 %	2
		Abbott Alinity Toxo IgG		21		
		Abbott Architect Toxo IgG		16		
		Bayer Advia Centaur Toxoplasma IgG		2		
		Beckman Coulter Access Toxo IgG EIA		1		
		bioMérieux Vidas Toxo IgG		12		
		BioRad Platelia Toxo IgG EIA		6		
		Chorus Toxo IgG		1		
		Diasorin Liaison Toxo IgG		29		
		Euroimmun Anti-Toxoplasma gondii IgG ELISA		2		
		Euroimmun Anti-Toxoplasma gondii IgG IIFT		2		
		Novatec NovaLisa Toxoplasma gondii IgG ELISA		1		
		Roche cobas/Modular/Elecsys Toxo IgG		26		
		Siemens Atellica Toxo IgG		4		
		Siemens Immulite Toxoplasma IgG		2		
	Total:		125		100 %	


ToxoAbM	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Positive		123		100 %	2
		Abbott Alinity Toxo IgM		19		
		Abbott Architect Toxo IgM		15		
		Bayer Advia Centaur Toxoplasma IgM		2		
		Beckman Coulter Access Toxo IgM EIA		2		
		bioMérieux Vidas Toxo IgM		12		
		BioRad Platelia Toxo IgM EIA		6		
		Chorus Toxo IgM		1		
		Diasorin Liaison Toxo IgM		28		
		Euroimmun Anti-Toxoplasma gondii IgM ELISA		1		
		Euroimmun Anti-Toxoplasma gondii IgM IIFT		2		
		Novatec NovaLisa Toxoplasma gondii IgM ELISA		2		
		Roche cobas/Modular/Elecsys Toxo IgM		27		
		Siemens Atellica Toxo IgM		4		
		Siemens Immulite Toxoplasma IgM		2		
	Total:		123		100 %	

Toxo IgG Avidity	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Not measurable		1		0 %	0
		Chorus Toxo IgG Avidity		1		
	Strong avidity		1		0 %	0
		Novatec NovaLisa Toxoplasma gondii IgG Avidity ELISA		1		
	Weak avidity		40		100 %	2
		Abbott Alinity Toxo IgG avidity		6		
		Abbott Architect Toxo IgG Avidity		3		
		bioMérieux Vidas Toxo IgG Avidity		11		
		BioRad Platelia Toxo IgG Avidity EIA		2		
		Chorus Toxo IgG Avidity		1		
		Diasorin Liaison Toxo IgG Avidity		8		
		Euroimmun Anti-Toxoplasma gondii IgG Avidity ELISA		3		

		Roche cobas/Modular/Elecsys Toxo IgG Avidity		5		
		TestLine Toxoplasma IgG Avidity EIA		1		
	Total:		42		95.2 %	


Sample S003

Sample S003 success rate




Sample S003 results	Responded	AVR success rate	Count
	Clinical interpretation	100 %	126
	ToxoAb	100 %	2
	ToxoAbA	-	8
	ToxoAbG	100 %	125
	ToxoAbM	100 %	123
	Toxo IgG Avidity	91.2 %	34
	Total:	99.3 %	418

Sample S003 Clinical interpretation




Clinical interpretation	Clinical interpretation	Further handling	Clinical interpretation count	Further handling count	AVR success rate	Clinical interpretation Score	Further handling Score
	Previous infection, no indication of primary infection		18		100 %	4	
		New sample requested		2	-		-
		Would be referred to another laboratory for further examination		2	-		-
	Previous infection, no indication of acute/recent infection		58		100 %	4	
		New sample requested		7	-		-
		Would be referred to another laboratory for further examination		6	-		-
	Laboratory does not give clinical interpretation		50		-	-	
		New sample requested		2	-		-
		Would be referred to another laboratory for further examination		4	-		-
	Total:		126		100 %		

Sample S003 ToxoAb



Positive

Sample S003 ToxoAbA



Negative Borderline Positive

Sample S003 ToxoAbG



Positive

Sample S003 ToxoAbM



Negative

Sample S003 Toxo IgG Avidity



Not measurable Strong avidity Weak avidity

ToxoAb	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Positive		2		100 %	2
		bioMérieux Vidas Toxo Competition		1		
		Euroimmun Anti-Toxoplasma gondii Screen ELISA (IgAGM)		1		
	Total:		2		100 %	
ToxoAbA	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Negative		3		-	-
		BioRad Platelia Toxo IgA EIA		2		

		Chorus Toxo IgA		1		
	Borderline		1		-	-
		BioRad Platelia Toxo IgA EIA		1		
	Positive		4		-	-
		BioRad Platelia Toxo IgA EIA		1		
		Chorus Toxo IgA		1		
		Euroimmun Anti-Toxoplasma gondii IgA ELISA		2		
	Total:		8			

ToxoAbG	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Positive		125		100 %	2
		Abbott Alinity Toxo IgG		21		
		Abbott Architect Toxo IgG		16		
		Bayer Advia Centaur Toxoplasma IgG		2		
		Beckman Coulter Access Toxo IgG EIA		1		
		bioMérieux Vidas Toxo IgG		12		
		BioRad Platelia Toxo IgG EIA		6		
		Chorus Toxo IgG		1		
		Diasorin Liaison Toxo IgG		29		
		Euroimmun Anti-Toxoplasma gondii IgG ELISA		2		
		Euroimmun Anti-Toxoplasma gondii IgG IIFT		2		
		Novatec NovaLisa Toxoplasma gondii IgG ELISA		1		
		Roche cobas/Modular/Elecsys Toxo IgG		26		
		Siemens Atellica Toxo IgG		4		
		Siemens Immulite Toxoplasma IgG		2		
	Total:		125		100 %	

ToxoAbM	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Negative		123		100 %	2
		Abbott Alinity Toxo IgM		19		
		Abbott Architect Toxo IgM		15		
		Bayer Advia Centaur Toxoplasma IgM		2		
		Beckman Coulter Access Toxo IgM EIA		2		
		bioMérieux Vidas Toxo IgM		12		
		BioRad Platelia Toxo IgM EIA		6		
		Chorus Toxo IgM		1		
		Diasorin Liaison Toxo IgM		28		
		Euroimmun Anti-Toxoplasma gondii IgM ELISA		1		
		Euroimmun Anti-Toxoplasma gondii IgM IIFT		2		
		Novatec NovaLisa Toxoplasma gondii IgM ELISA		2		
		Roche cobas/Modular/Elecsys Toxo IgM		27		
		Siemens Atellica Toxo IgM		4		
		Siemens Immulite Toxoplasma IgM		2		
	Total:		123		100 %	

Toxo IgG Avidity	Result	Methodics	Result count	Methodics count	AVR success rate	Result Score
	Not measurable		1		0 %	0
		Chorus Toxo IgG Avidity		1		
	Strong avidity		31		100 %	2
		Abbott Alinity Toxo IgG avidity		2		
		Abbott Architect Toxo IgG Avidity		3		
		bioMérieux Vidas Toxo IgG Avidity		6		
		BioRad Platelia Toxo IgG Avidity EIA		2		
		Chorus Toxo IgG Avidity		1		
		Diasorin Liaison Toxo IgG Avidity		7		
		Euroimmun Anti-Toxoplasma gondii IgG Avidity ELISA		3		
		Novatec NovaLisa Toxoplasma gondii IgG Avidity ELISA		1		
		Roche cobas/Modular/Elecsys Toxo IgG Avidity		5		
		TestLine Toxoplasma IgG Avidity EIA		1		
	Weak avidity		2		0 %	0
		Abbott Alinity Toxo IgG avidity		2		
	Total:		34		91.2 %	

Report Info**PARTICIPANTS**

Altogether 116 laboratories from 21 countries participated in this EQA round.

REPORT INFO

The results are divided into groups according to the method stated by the laboratory and presented in laboratory-specific tables. Accepted results are marked with green color and laboratory's own result with a black radio button . In the scoring report you will find summaries of overall success rate and sample specific success rates (%). Sample specific interpretations are shown in pie diagrams as percentages and the total interpretation and methodic counts in the tables. If you have not reported any results you will get a note: "You have not responded in time, only global report is available."

For information on report interpretation and performance evaluation, please see the "EQAS Interpretation guidelines" in LabScala User instructions. In case you have any questions regarding the reports, please contact the EQA Coordinator.

SCORING

The round is scored based on test results and clinical interpretations when 60% or more of the participants report the expected result and when at least three results are reported.

The following general rules are applied:

Correct/expected test result 2/2 points
False/deviating test result 0/2 points
Correct/expected clinical interpretation 4/4 points
False/deviating clinical interpretation 0/4 points

The performance of the laboratory is assessed by the Own success rate (%). The target is 100%. The examination-specific scores obtained by the laboratory in the round are converted to Own success rate per sample (scores/maximum scores*100). The Laboratory's Own success rate is the average of the sample success rates.

The success rate for the entire round (AVR success rate) is calculated from the total number of scores given to the results per sample (all scores/maximum scores*100). The AVG success rate of the entire round is the average of the sample success rates. The difference in the Laboratory's Own success rate (%) to the corresponding numbers for the entire round is shown in the table.

External Quality Assessment Scheme

Toxoplasma, antibodies Round 1, 2023

Specimens

Samples of this EQA round were human plasma or serum, each of which originated from a single separate donor. Based on the pre-testing and the results obtained in the round, the samples were homogeneous, stable, and suitable for the external quality assessment scheme. The materials were sent without any temperature control packaging.

The accepted results were as follows:

Sample S001 (LQ769723011)

ToxoAb: Positive
ToxoAbG: Positive
ToxoAbM: Positive
ToxoAbA: Positive
Avidity: Weak avidity
Clinical interpretation: Acute/recent toxoplasma infection

Sample S002 (LQ769723012)

ToxoAb: Positive
ToxoAbG: Positive
ToxoAbM: Positive
ToxoAbA: Positive
Avidity: Weak avidity
Clinical interpretation: Acute/recent toxoplasma infection

Sample S003 (LQ769723013)

ToxoAb: Positive
ToxoAbG: Positive
ToxoAbM: Negative
ToxoAbA: Indeterminate
Avidity: Strong avidity
Clinical interpretation: Previous infection, no indication of acute/recent/primary infection

Report info

Please see the description of the data analysis on the last page of the laboratory-specific reports and global reports. It is important to read the Final report first, because it contains important information of the samples and results in each round.

Comments – expert

Sample S001: A 48-year-old woman, diagnosed with lymphadenopathy 3 weeks earlier. The serological results and the clinical picture are consistent with a recent primary toxoplasma infection, which does not require specific treatment in a healthy adult.

Sample S002: A 10-year-old child with prolonged fever and lymphadenopathy. The serological results and the clinical picture are consistent with a recent primary toxoplasma infection, which does not require specific treatment in a healthy child.

2023-03-21

FINAL REPORT

Product no. 5420

Subcontracting: Sample preparation, sample pretesting

Samples sent	2023-01-31
Round closed	2023-02-24
Expected results	2023-03-01
Final report	2023-03-21

Request for correction

Typing errors in laboratory's result forms are on laboratory's responsibility. Labquality accepts responsibility only for result processing. Requests must be notified by writing within three weeks from the date of this letter.

Authorized by

EQA Coordinator
Outi Rauta
outi.rauta@labquality.fi

EQA Coordinator

Pia Eloranta
pia.eloranta@labquality.fi

Expert

Dos., Head of division
Maija Lappalainen
HUS Diagnostic Center, HUSLAB,
Clinical microbiology, Finland

Labquality Oy

Kumpulantie 15
FI-00520 HELSINKI
Finland

Tel. + 358 9 8566 8200

Fax + 358 9 8566 8280

info@labquality.fi

www.labquality.com



Sample S003: A 40-year-old man, recently diagnosed as HIV positive. Serological results indicate a previous toxoplasma infection. In an HIV-positive patient effective antiviral treatment prevents toxoplasma reactivations with severe symptoms.

Exceptions in scoring

Sample S003: IgA results not scored due to high dispersion.

Annex

The quantitative ToxoAbG test results of samples S001-S003 from participants that reported their results in IU/mL are presented in Annex 1.

End of report

Copyright © Labquality Oy

Labquality does not permit any reproduction for commercial purposes of any portion of the material subject to this copyright. Labquality prohibits any use of its name, or reference to Labquality EQA program, or material in this report in any advertising, brochures or other commercial publications. Labquality EQA data do not necessarily indicate the superiority of instruments, reagents, testing equipments or materials used by participating laboratories. Use of Labquality EQA data to suggest superiority or inferiority of equipments or materials may be deceptive and misleading. Proficiency test results are handled confidentially. Labquality will not issue any statements to third parties of the performance of laboratories in external quality assessment schemes unless otherwise agreed.

		S001	S002	S003
Test method	N	Quantitative ToxoAbG result (IU/mL)	Quantitative ToxoAbG result (IU/mL)	Quantitative ToxoAbG result (IU/mL)
Abbott Alinity Toxo IgG	21	188.4	200	200
		170.67	200	200
		194	200	200
		196.27	200	200
		199.1	200	200
		199.8	549.06	200
		200	599.23	451.2
		200	608	516.7
		200	625	519.38
		547.5	630.4	525.3
		559.9	666	569.83
		>200	669.1	588.1
		>200	746.5	719
		>200	378332	590235
		151.6	>200	>200
		187.90	>200	>200
		191.3	>200	>200
		198.10	>200	>200
		198.4	>200	>200
		200.0	>200	>200
		436.5	539.6	
Abbott Architect Toxo IgG	15	134.9	163	457.2
		179	618.4	555.3
		199.7	619.9	577
		545.8	681	589.2
		571	>200	>200
		>200	>200	>200
		>200	>200	>200
		151.5	>200	>200
		178.5	>200	>200
		180.9	>200	>200
		185.5	>200	>200
		187.0	>200	>200
		187.1	>200	>200
		189.2	521.2	499.3
		541.1	635.9	569.2
bioMérieux Vidas Toxo IgG	9	284	170	300
		287	175	952
		264	225	>300
		273.0	233	>300
		213	255	>300
		187	264	>300
		>300	285	>300
		>300	>300	>300
		243,00	289.0	>300

		S001	S002	S003
Test method	N	Quantitative ToxoAbG result (IU/mL)	Quantitative ToxoAbG result (IU/mL)	Quantitative ToxoAbG result (IU/mL)
Roche cobas/Modular/Elecsys	24	618	468	650
		403.9	330	650
		439.3	334.3	650
		458	341.9	650
		489	367.2	6149
		492.3	374.9	7164
		492.91	376.7	7771
		515.9	377.4	8111
		523	378.9	8246
		530	383.4	8518
		533	384	8526
		544	394.8	>650
		547	397.2	>650
		553.4	406.3	>650
		571.8	409	>650
		586.6	420.4	>650
		607	433.5	>650
		630.2	439	>650
		631	444	>650
		636	451	>650
		>650	473	>650
		>650	506	>650
		481.8	380.2	>650
		555.7	397.3	650 -
Diasorin Liaison Toxo IgG	23	191	148	350
		193	173	352
		215	184	353
		220	194	376
		226	209	398
		252	211	400
		255	216	400
		263	223	892
		269	223	1000
		275	226	1040
		281	232	1060
		284	234	>400
		295	239	>400
		295	253	>400
		309	253	>400
		313	254	>400
		314	261	>400
		316	270	>400
		334	277	>400
		340	283	>400
		398	305	>400
		>400	359	>400
		272.00	245.00	>400